I don’t mean that literally, of course, but metaphorically. Back when Prozac first hit national consciousness here in the US in the early 90s there was a huge backlash against it, much like the one we’re seeing against the GLP/GIPs.

Every magazine had a special issue with a bottle of pills lit by scary, dramatic lighting for a cover. There was a constant discourse of hysteria and pearl clutching like: “you’ll have to be on it forever!”, “it doesn’t really fix anything!”, “it’s so expensive!”, “what if they give it to children?!?”, “oh no the side effects!”. Every self appointed expert had a reason you shouldn’t take it: “you don’t need it, you just need God”, “you just need to get tough”, “it’s a cop out for the weak”, etc, etc. Even many therapists and psychiatrists spoke against it, often more afraid for their jobs than anything else, “what if we fix everything with a pill, what does that mean for psychiatry?”

And now, 30 years later we have a much better understanding of anti-depressants. They are a common prescription and much of society accepts them the same way we accept people being on statins, insulin or ibuprofen. They didn’t destroy psychiatry, make everyone become mindless drones or create a bunch of psychopaths. And they became a whole lot more affordable.

On the other hand, Prozac itself would be an odd prescription today as there are much better, more targeted medications with fewer side effects.

I strongly believe the same thing will happen with semaglutide and tirzepatide, but probably much faster due to the much larger number of potential patients. In ten years the new family of weight loss drugs will be commonly used and accepted by society, but they probably won’t be semaglutide or tirzepatide but rather some new, more targeted meds that are cheap and have far fewer side effects.

But that doesn’t mean I’m going to wait a decade to lose this weight.

  • @sqw
    link
    English
    15 months ago

    seems the jury is out until we can see the effects of long-term use

    • @BartyDeCanterOPM
      link
      25 months ago

      The thing is, we already have long-term data for GLP1-RAs as a class of drug. Exenatide was approved in 2005, Liraglutide in 2010, Dulaglutide in 2014, etc. See https://en.wikipedia.org/wiki/GLP-1_receptor_agonist#Approved for more. This shows that GLP1-RAs as a general concept are long term safe, it’s just a question of effectiveness and effects for any specific one.